Ramcopharm Ltd. was established in 1993. The main activity of the company is the production of nutritional supplements on herbal basis - products of dry extracts, essential oils and combinations of vitamins in capsule and tablet form and pharmaceuticals. The Company's main activity code is "10.89 Manufacture of other non-food products not elsewhere classified" At present the company has more than 90 currently in production products that have a reputation of high quality and sought after by consumers. Some of the most popular products of the company are Rozkalipt, Ginkgo Biloba, LAKS, Stevia, Blueberry +, and others. The Company has implemented in production and a medicinal product - Calium Yodidum used to protect people from radioactive contamination. Most of the company's products are patent protected as utility models and trademarks. Ramcopharm Ltd. has its own factory built under conditions of GMP / Good Manufacturing Practice / and licensed for the manufacture of medicinal products from Executive Agency for Medicines (BDA). In order to improve the production capacity of the company and its export potential this project provides for the purchase of two new machines - for the production of food additives dosed in hard capsules and packing type "Sachet". By their purchase will be achieved the project’s objective - improving the competitiveness of Ramcopharm Ltd. by increasing production capacity, export potential and diversification of the product range. The project "Improvement of production capacity and increasing the export potential of Ramcopharm Ltd." includes the following activities: 1. Improvement of production processes in the activity of Ramcopharm LTD. 2. Diversification of the range of products manufactured by Ramcopharm LTD. 3. Implementation of new technologies to improve resource efficiency and effectiveness in the production process of Ramcopharm LTD.
Overview
Status | Closed (completion date) |
---|---|
Start date | 23 Dec, 2015 |
End date | 22 Mar, 2017 |
Contract date | 23 Dec, 2015 |
Programme
Beneficiary
Financial information
Total cost | 604,351.47 |
---|---|
Grant | 271,958.16 |
Self finance | 332,393.31 |
Total paid | 271,958.16 |
EU participation percent | 85.0% |
Location